Yardley, et al. [120] reported, in a Phase II trial (N = 168), that for HER2-negative breast cancer patients treated with ixabepilone and cyclophosphamide as neoadjuvant therapy, only 8% of them developed SPN grade 3 [121]. This evidence concerns the gene ERBB2 and breast cancer.